Position paper 29 Jun 2022

IFPMA Artificial Intelligence Principles

Artificial Intelligence (AI) has the potential to bring about positive transformations in science and society, including in healthcare. As a powerful enabler of progress and innovation, AI can increase individual well-being and contribute to the common good. However, while offering tremendous opportunities, relatively new AI technology could also raise concerns relating to potential misuse and inadequate accountability, as well as systemic risks inherent to algorithmic bias and discrimination.

Expert insight 29 Jun 2022

Caring for chronic diseases in lower-resource settings

In the wake of COVID-19, lower-resourced settings need sustainable healthcare more than ever to build back better. Promising solutions are at hand.

Position paper 23 Jun 2022

Regulatory agilities applied to quality processes

This policy briefing summarizes trends in reported experiences (from primary and secondary research) in the use of regulatory agilities applied to quality observed since the start of the pandemic, some reported challenges to their implementation and forward-looking recommendations, whether to prepare for the next pandemic or strengthen standard normative processes to accelerate patient access to safe and effective medicines and vaccines.

Position paper 23 Jun 2022

Regulatory agilities applied to clinical trials

This policy briefing summarizes trends in reported experiences (from primary and secondary research) in the use of regulatory agilities in clinical trials observed since the start of the pandemic, reported challenges to their implementation and forward looking recommendations, whether to prepare for the next pandemic or to modernize standard normative processes to accelerate patient access to safe and effective medicines.

Position paper 23 Jun 2022

Regulatory agilities and regulatory processes

This policy briefing summarizes trends in reported experiences (from primary and secondary research) in the use of these agilities observed since the start of the pandemic, some reported challenges to their implementation and forward-looking recommendations, whether to prepare for the next pandemic or to strengthen standard normative processes to accelerate patient access to safe and effective medicines and vaccines.

Press release 21 Jun 2022

Global pharmaceutical industry leaders meet with German officials to discuss life sciences innovation in Germany and global pandemic response involving the G7

The Biopharmaceutical CEO Roundtable (BCR) delegation exchanged views on how the German government and industry can work together to reinvigorate innovation across the life sciences eco-system.

Expert insight 21 Jun 2022

Collaboration can help find a vaccine within first 100 days

Our efforts against COVID-19 have surfaced critical learnings, including the need to establish a global foundational capability, fit for purpose ahead of the next health emergency.

Expert insight 21 Jun 2022

Vaccines are making an impact through vaccinations

Over the last two years, the global healthcare community’s efforts in mounting a response to COVID-19 have materialised. This pandemic has brought home the power of vaccines to save lives and protect the vulnerable.

Press release 17 Jun 2022

Pharmaceutical industry expresses deep disappointment with decision on waiving intellectual property rights adopted at the World Trade Organization Ministerial Conference

IFPMA, the body representing biopharmaceutical companies in Geneva, expresses deep disappointment with the decision taken to adopt a TRIPS waiver, despite intellectual property (IP) not being a barrier to vaccine scale-up and wide acknowledgment of vaccines surplus.

Statement 15 Jun 2022

IFPMA’s comments on annotated outline of a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response

The biopharmaceutical industry has been at the forefront of the response to the current pandemic and, as a result, is uniquely positioned to contribute to future pandemic preparedness discussions. We welcome the opportunity to comment on this white paper and stand ready to contribute with the private sector’s expertise as the INB’s work progresses. Given...

Position paper 9 Jun 2022

Clinical research in resource-limited settings

Read our perspective, which includes examples and case studies of how members contribute their expertise and knowledge to expand the clinical research infrastructure in LMICs.

Statement 9 Jun 2022

Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12)

The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the “Quad compromise” is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry’s ability to...